Elevidys (delandistrogene moxeparvovec-rokl) — Medical Benefit Drug Policy (coverage criteria)
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0126F alerts
Get alerted when Policy 2026D0126F changes without checking for updates manually.
Monitor payer policy activity
Defines medical benefit coverage criteria and limits for Elevidys gene therapy for treatment of Duchenne muscular dystrophy (DMD) under UnitedHealthcare Commercial/Community Plan benefits; affects prescribers, infusion providers, and prior authorization reviewers.
Revised coverage criteria; added criterion requiring the provider does not request a planned inpatient admission for the sole purpose of administering Elevidys.
Archived previous policy version 2025D0126E.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.